Atara Biotherapeutics Full Year 2023 Earnings: Revenues Disappoint

Atara Biotherapeutics Inc +1.06%

Atara Biotherapeutics Inc




Atara Biotherapeutics (NASDAQ:ATRA) Full Year 2023 Results

Key Financial Results

  • Net loss: US$276.1m (loss widened by 21% from FY 2022).
  • US$2.61 loss per share (further deteriorated from US$2.24 loss in FY 2022).
NasdaqGS:ATRA Earnings and Revenue Growth March 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Atara Biotherapeutics Revenues Disappoint

Revenue missed analyst estimates by 53%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 3.7% from a week ago.

Risk Analysis

We should say that we've discovered 6 warning signs for Atara Biotherapeutics (3 are a bit concerning!) that you should be aware of before investing here.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via